<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gordon, Debra</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Pratley, Richard</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Recent Data from LEAD</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">In patients with diabetes, vascular conditions are responsible for the majority of morbidity, mortality, and cost that are attributed to the disease [Centers for Disease Control and Prevention. National Diabetes Fact Sheet. 2007]. The Liraglutide Effect and Action in Diabetes [LEAD; NCT00700817] trials are designed to evaluate the efficacy and safety of glucagon-like peptide-1 agonist compared with existing antidiabetic therapies.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>